Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,600
- 试验地点
- 1
- 主要终点
- New cardiovascular events (MACE)
研究概览
简要总结
Study hypothesis: Multifactorial risk reduction in coronary heart disease can reduce the risk of new coronary heart disease and death
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •acute myocardial infarction, CABG or PCI
排除标准
- •Age < 18 and age > 80
- •critical illness
- •drug abuse
研究组 & 干预措施
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
干预措施: smoking cessation (Behavioral)
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
干预措施: betablocker, diuretics, ACEI, ARB, (Drug)
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
干预措施: statins, ezetimibe (Drug)
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
干预措施: training (Behavioral)
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
干预措施: influenza vaccine (Biological)
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
干预措施: metformin, glimepiride, insulin (Drug)
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
干预措施: weight reduction (Behavioral)
结局指标
主要结局
New cardiovascular events (MACE)
时间窗: 3 years
次要结局
未报告次要终点
研究者
Sissel Ledang
Sorlandet Hospital HF
Sorlandet Hospital HF